All Stories

Boston biotech Bambusa banks $90M for next-gen bispecifics

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions.

Feb 14, 2025 - 17:21
 0
Boston biotech Bambusa banks $90M for next-gen bispecifics
Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions.
Read More

Tags:

Previous Article

Moderna shoulders $238M contract manufacturing cancellation charge in Q4

Next Article

CDC to lose one-tenth of workforce under Trump administration probationary job cuts

Related Posts

Michigan CRO buys Exploristics for its cloud-based modeling platform

Michigan CRO buys Exploristics for its cloud-based mode...

Feb 12, 2025  0

'Patently illegal': NIH and HHS face new lawsuit over $1.1B in revoked research grants

'Patently illegal': NIH and HHS face new lawsuit over $...

Apr 2, 2025  0

Fierce Biotech Fundraising Tracker '25: Epicrispr claims $68M series B; Character clinches $93M

Fierce Biotech Fundraising Tracker '25: Epicrispr claim...

Mar 27, 2025  0